Depo-Provera Meningioma Symptoms: Warning Signs Every Long-Term User Needs to Know

What Is a Meningioma? Understanding the Tumor at the Center of This Lawsuit

A meningioma is a tumor that grows from the meninges — the three protective membrane layers that surround and cushion the brain and spinal cord. Unlike tumors that originate within brain tissue itself, meningiomas arise from this outer covering. Because of where they start, they are technically classified as "extra-axial" tumors: they sit outside the brain rather than inside it. But do not let that description give you false comfort. Even a tumor that begins on the outer wrapping of the brain can compress and damage brain tissue as it grows, with serious and sometimes irreversible consequences.

According to the National Institutes of Health (NIH), meningiomas are the most common primary brain tumor in adults, accounting for approximately 30% of all brain and central nervous system tumors diagnosed in the United States each year. The American Brain Tumor Association estimates roughly 42,000 new meningioma diagnoses annually in the U.S. alone. They are significantly more common in women than men — occurring roughly twice as often — a disparity that researchers have long suspected is driven by hormonal factors, particularly progesterone.

WHO Grading: Benign Does Not Mean Harmless

The World Health Organization (WHO) grades meningiomas on a three-tier scale that reflects how aggressive the tumor is likely to behave:

• WHO Grade I (Benign): The vast majority of meningiomas — roughly 80% — fall into this category. They grow slowly, are less likely to invade surrounding brain tissue, and have a better prognosis after treatment. However, "benign" does not mean asymptomatic or harmless. A Grade I tumor that grows near critical brain structures can cause severe disability and require major surgery.
• WHO Grade II (Atypical): These tumors make up about 15–18% of meningiomas. They grow faster than Grade I tumors, are more likely to recur after surgical removal, and carry a greater risk of causing neurological damage. Treatment is more aggressive and monitoring must continue indefinitely after surgery.
• WHO Grade III (Anaplastic/Malignant): The rarest form, accounting for roughly 1–3% of cases. These tumors behave like cancer — they grow aggressively, often invade brain tissue, and have a significantly worse prognosis. Treatment typically involves surgery, radiation, and sometimes chemotherapy.

The meningiomas that have been most closely associated with progestogen hormone use — including Depo-Provera — are predominantly Grade I tumors. But even these "benign" Grade I meningiomas are being surgically removed from women's brains, leaving them with permanent cognitive changes, vision damage, hearing loss, or other neurological deficits that alter their lives in lasting ways.

Where in the Brain Do Meningiomas Grow?

Meningiomas can arise anywhere along the meninges, and their location determines which neurological functions are disrupted. The most common sites include the convexity (the domed top of the skull), the falx cerebri (the fold of dura between the brain's two hemispheres), the parasagittal region (along the midline), the sphenoid wing (near the eye sockets at the base of the skull), the skull base, the posterior fossa (behind the brainstem and cerebellum), and occasionally the spinal canal. Each location produces a different constellation of symptoms — which is exactly why this article breaks them down by location in detail below.

Why Depo-Provera Users Face Elevated Risk

Depo-Provera — manufactured by Pfizer and containing the synthetic progestogen medroxyprogesterone acetate (MPA) — has been used as a contraceptive injection since the FDA approved it in 1992. A single injection lasts approximately 13 weeks. For the millions of women who used it as their primary birth control method over multiple years, the accumulated exposure to MPA has now become the subject of a major scientific and legal reckoning.

The biological mechanism is well-established in the research literature. Meningioma cells frequently express progesterone receptors — the molecular "docking stations" that respond to progesterone and progesterone-like hormones. When a synthetic progestogen like MPA continuously stimulates these receptors over months and years, it may trigger abnormal cell proliferation in the meninges. Researchers have also noted that many meningiomas associated with progestogen use shrink or stabilize after the hormone is stopped — direct evidence of the tumor's hormone-dependence.

Despite decades of scientific signals, the FDA did not approve a meningioma warning label for Depo-Provera until December 17, 2025. This was the same warning that French regulators had issued years earlier, and that had already prompted the withdrawal of certain high-dose progestogen products from the French market. Critics — including plaintiffs' attorneys and patient advocates — argue that Pfizer possessed enough evidence to warn patients much earlier and failed to do so.

As of April 2026, 3,490 cases are consolidated in MDL No. 3140 in the Northern District of Florida, with the first bellwether trial — Blonski v. Pfizer — scheduled for December 7–14, 2026. The outcome of that trial is expected to have significant implications for how remaining cases are valued and resolved.

Symptoms by Tumor Location: The Most Important Section to Read

This is the section that sets this article apart from a generic overview of meningiomas. Because the brain is divided into functionally distinct regions, a meningioma growing in one area will produce a completely different set of symptoms than a tumor growing somewhere else. Many women see multiple doctors over months or years without anyone connecting their symptoms to a brain tumor — because the symptoms look like migraine, inner ear problems, depression, or normal aging. Understanding the location-specific pattern can help you recognize whether your symptoms deserve further investigation.

Sphenoid Wing / Temporal Region Meningioma — Most Common in Depo-Provera Cases

Research specifically examining progestogen-associated meningiomas has found a disproportionate concentration at the sphenoid wing — the butterfly-shaped bone at the base of the skull near the eye sockets. This is not coincidental. The sphenoid ridge and adjacent skull base areas appear to have particularly high concentrations of progesterone receptor-positive meningeal tissue, which may explain why they are especially susceptible to hormone-driven tumor growth.

Because these symptoms so closely mimic optic neuritis, ocular migraine, or thyroid eye disease, women with sphenoid wing meningiomas are often seen by ophthalmologists and optometrists first — and the neurological origin may be missed for a year or more. If you have had repeated eye exams that do not explain your vision symptoms, and you have a history of long-term Depo-Provera use, a brain MRI with contrast is warranted.

Frontal Lobe Meningioma Symptoms

The frontal lobe governs executive function, personality, emotional regulation, working memory, planning, and initiative. A meningioma that presses on the frontal lobe from its outer surface can disrupt all of these functions in ways that are frequently mistaken for psychiatric illness, burnout, or "normal aging."

• Personality changes: Friends and family may notice that you seem "different" — less engaged, more impulsive, less emotionally reactive, or conversely, more irritable and easily frustrated. The person experiencing this often does not notice it themselves because the affected area is responsible for self-monitoring.
• Cognitive slowing and brain fog: Difficulty keeping up with conversations, taking longer to process information, forgetting the point of what you were saying mid-sentence, or feeling like your thinking is "behind a curtain." This is often dismissed as stress, anxiety, or the natural toll of a busy life.
• Memory problems: Specifically short-term memory — difficulty retaining new information, frequently misplacing items, forgetting appointments or commitments. Long-term memories tend to remain intact until later stages.
• Loss of initiative or motivation: A dramatic reduction in the drive to start or complete tasks. Hobbies feel pointless. Responsibilities pile up not because of depression exactly, but because initiating action feels enormously effortful.
• Frontal headaches: Pressure or aching behind the forehead, often dull and persistent, frequently worse in the morning.
• Seizures: Frontal lobe seizures can be subtle — brief staring spells, involuntary movements of an arm or leg, or a sudden unexplained feeling of fear or unreality. They are often not recognized as seizures by the person experiencing them.

Skull Base / Posterior Fossa Meningioma Symptoms

Meningiomas at the skull base or in the posterior fossa (the lower, rear portion of the skull that houses the cerebellum and brainstem) compress structures responsible for hearing, balance, facial sensation, and coordination. These tumors can be particularly insidious because their symptoms so closely resemble common, non-threatening conditions.

• Unilateral hearing loss: Gradual reduction in hearing in one ear — not both. The one-sided nature is a key distinguishing feature from typical age-related hearing loss, which affects both ears roughly equally.
• Tinnitus: Ringing, buzzing, hissing, or roaring in one ear. This can be the first symptom to appear, sometimes years before other symptoms develop.
• Balance problems and unsteadiness: Difficulty maintaining balance when walking, particularly in low light or when the eyes are closed. Bumping into doorframes, feeling the floor "shift" unexpectedly, needing to touch walls for stability.
• Vertigo: A spinning sensation — often described as the room revolving — that may be triggered by position changes or may occur spontaneously. This is frequently misdiagnosed as benign paroxysmal positional vertigo (BPPV) or Meniere's disease.
• Facial numbness or tingling: A pins-and-needles sensation or reduced feeling on one side of the face, which may extend to the lips or chin. Sometimes described as feeling like a dental anesthetic wearing off, but lasting days or weeks.
• Facial weakness or asymmetry: Drooping or asymmetry of one side of the face, difficulty smiling evenly, or drooping of one eyelid.
• Difficulty swallowing: In more advanced cases, when the tumor compresses the lower brainstem, swallowing may feel effortful or cause choking on liquids.

One-sided hearing loss and tinnitus in particular are frequently sent to audiologists and ENT specialists rather than neurologists, and are often attributed to noise damage, aging, or Meniere's disease without brain imaging ever being obtained. If you have new one-sided hearing loss and you have used Depo-Provera for a year or more, this combination deserves a neurological workup.

Parasagittal / Falcine Meningioma Symptoms

Meningiomas that grow along the falx cerebri (the membrane running down the center of the brain) or adjacent to the superior sagittal sinus (a large venous channel running along the top of the brain) sit in a critical position. As they grow, they typically compress the medial surface of both hemispheres, particularly the motor strips that control the legs.

• Leg weakness or heaviness: Progressive difficulty with walking — legs feel heavy or unreliable, particularly when going up stairs. One leg may drag slightly. This may be mistaken for a hip or lumbar spine problem.
• Difficulty walking and coordination problems: A subtle but worsening change in gait — shuffling, widening the stance for balance, or tripping without obvious cause.
• Urinary urgency or incontinence: Loss of bladder control or urgency that cannot be explained by a urologic cause. This is particularly common when parasagittal tumors compress the regions governing bladder function. Many women attribute this to pelvic floor changes after pregnancy and never connect it to a neurological source.
• Headaches along the top of the head: Localized pressure or pain running front-to-back along the midline of the skull.
• Leg or foot seizures: Jerking or stiffening movements starting in one foot and moving upward, sometimes called a "Jacksonian march." These seizures are caused by abnormal electrical activity in the motor strip and are strongly associated with parasagittal meningioma.

General Symptoms That All Meningiomas Can Cause

Beyond the location-specific patterns above, there are several symptoms that meningiomas can cause regardless of where they are growing. These are caused by the general effect of an expanding mass inside a closed, rigid skull — a phenomenon called "mass effect" or increased intracranial pressure.

Progressive Headaches — Especially Morning Headaches

The headache pattern associated with meningioma has a distinctive quality that differs from tension headaches or migraines. These headaches tend to be progressive — meaning they start mild and gradually worsen over weeks or months. They are typically described as a dull, steady pressure rather than a throbbing pain. The hallmark feature is that they are often worst upon waking in the morning and tend to improve somewhat after the person gets up and moves around for an hour or two.

This morning-dominant pattern exists because cerebrospinal fluid (CSF) pressure is naturally higher when lying flat overnight. A tumor that is already creating pressure in the skull will amplify this effect, causing the pressure to build to its peak by morning. When the person rises and CSF redistributes, the headache partially eases — giving the false impression that the headache is functional or stress-related rather than structural.

Meningioma headaches also typically do not respond well to over-the-counter pain medications. If you have been taking ibuprofen, acetaminophen, or even prescription migraine medications regularly without adequate relief, and the headaches have been worsening over months rather than cycling in and out, this is a meaningful clinical signal.

Nausea and Vomiting

Nausea that accompanies headaches and is not related to gastrointestinal illness or food can be a sign of elevated intracranial pressure. In more advanced cases, vomiting may occur — sometimes projectile in nature — without significant preceding nausea. This is called "vomiting without prodrome" and is a recognized symptom of elevated intracranial pressure from any cause, including an expanding tumor.

Cognitive Changes and Memory Decline

Even meningiomas that are not located in the frontal lobe can cause diffuse cognitive changes by increasing pressure throughout the brain. Women may notice difficulty with word-finding (called anomia — the experience of knowing what you want to say but being unable to retrieve the word), slower processing speed, increased forgetfulness, reduced ability to multitask, or a general sense that their thinking is not as sharp as it used to be. These symptoms are frequently attributed to perimenopause, depression, anxiety, or sleep deprivation.

Seizures

A significant proportion of meningioma patients experience a seizure at some point during the tumor's development, either before or after diagnosis. Seizures may be "generalized" (involving the whole body, with loss of consciousness) or "focal" (affecting just one part of the body, with the person remaining conscious but experiencing involuntary movements, sensory disturbances, or a feeling of unreality). Focal seizures are particularly easy to miss or misidentify — they may feel like a brief "spacing out" episode, an unexplained smell or taste, a sense of deja vu, or a sudden feeling of fear with no apparent trigger.

Why These Symptoms Are So Often Missed or Misdiagnosed

If you have been told your headaches are migraines, your vision changes are from dry eyes or refractive error, your hearing loss is from noise exposure, your balance problems are from inner ear crystals, or your cognitive changes are from anxiety or depression — and you have used Depo-Provera for years — you are not alone. The misdiagnosis rate for meningioma is substantial, and there are structural reasons why this keeps happening.

Slow Growth Masks the Tumor's Presence

Most Grade I meningiomas grow extremely slowly — sometimes only a few millimeters per year. This means the brain has time to "adapt" to the gradually increasing pressure, compensating in ways that mask the severity of the underlying problem. Symptoms emerge slowly enough that they are easy to dismiss as stress or lifestyle factors. By the time symptoms are severe enough to demand attention, the tumor may have been growing for five, ten, or even fifteen years.

Symptoms Mimic Extremely Common Conditions

Nearly every symptom of a meningioma has a more common "innocent" explanation that a physician will reach for first:

• Headaches → migraine, tension headache, sinus headache
• Vision changes → refractive error, dry eye, ocular migraine
• Hearing loss and tinnitus → noise damage, age-related hearing loss, Meniere's disease
• Balance problems and vertigo → BPPV (inner ear crystals), labyrinthitis, vestibular neuritis
• Cognitive changes → depression, anxiety, ADHD, perimenopause, hypothyroidism
• Leg weakness → lumbar spine disease, hip arthritis, peripheral neuropathy
• Urinary urgency → bladder overactivity, pelvic floor dysfunction, UTI
• Personality changes → depression, bipolar disorder, stress

Primary care physicians operate in an environment where they must rule in the most likely diagnosis first, and meningioma is statistically rare enough that it does not immediately appear on the differential. Without brain imaging, the tumor is simply invisible. And brain imaging — particularly an MRI with contrast — is not ordered unless the physician specifically thinks to look for a brain mass.

Depo-Provera History Is Often Not Disclosed or Not Considered

Many women do not volunteer their contraceptive history when seeing a neurologist or primary care doctor for headaches. And even when they do, most physicians — until December 2025, when the FDA finally updated the Depo-Provera label — were not connecting long-term Depo-Provera use to elevated meningioma risk. This is one of the most significant failures in this entire story: for decades, the link between synthetic progestogens and meningioma was documented in the scientific literature, but practicing physicians were not being warned by the drug's label. That gap is now at the core of the ongoing litigation against Pfizer.

The "Incidental Discovery" Scenario

A significant number of meningiomas are discovered not because a patient reported neurological symptoms, but because imaging was obtained for an entirely unrelated reason. This is called an "incidental" finding, and it is more common than most people realize. Studies suggest that up to 2.3% of the general adult population may have a small, asymptomatic meningioma detectable on MRI — though the vast majority of these never progress to cause symptoms in average-risk individuals.

Common scenarios in which a meningioma is discovered incidentally include:

• After a car accident: CT or MRI of the head ordered to rule out traumatic brain injury reveals an unexpected mass.
• During workup for another condition: A brain MRI ordered to evaluate possible multiple sclerosis, aneurysm screening, or unexplained neurological complaints uncovers a meningioma that was not the focus of the scan.
• Screening after a family member's diagnosis: A sibling or parent is diagnosed with a brain tumor, prompting the patient to request imaging, which reveals their own asymptomatic meningioma.
• Preoperative brain imaging: Imaging obtained before an unrelated procedure that includes a brain scan.

If you are a long-term Depo-Provera user and have had any brain imaging in the past several years, it is worth requesting a copy of the radiology report to review whether any incidental finding was noted — even one described as "small" or "likely benign." Radiologists routinely recommend follow-up imaging for incidental meningiomas, and those recommendations are sometimes not clearly communicated to patients. A tumor that was "incidentally noted" in a prior scan and has been growing since then may now be clinically significant.

What to Tell Your Doctor If You Have Concerns

If you are a current or former Depo-Provera user who is experiencing any of the symptoms described in this article, here is how to approach your medical provider in a way that maximizes the chance of getting the right evaluation.

Disclose Your Complete Depo-Provera History

Do not assume your doctor knows your contraceptive history — or that it is in your current chart. Before your appointment, try to reconstruct the timeline of your Depo-Provera use: when you started, when (if ever) you stopped, and approximately how many years or injections you received. The critical threshold in the litigation and the research is 12 consecutive months of use, so if you were on Depo-Provera for a year or more, make sure your doctor is explicitly aware of this and that it is documented in your chart.

If your doctor is not familiar with the FDA's December 2025 meningioma warning for Depo-Provera, you can mention it directly. Say: "I've read that the FDA added a meningioma warning to Depo-Provera in December 2025, and given my history of using it for [X] years and my current symptoms, I'd like to discuss whether I need brain imaging."

Ask Specifically for an MRI With Contrast

Not all brain imaging is created equal for detecting meningiomas. Specifically request:

• MRI with and without gadolinium contrast: This is the gold standard for meningioma detection. Meningiomas enhance dramatically with contrast (they light up brightly), making them easy to identify and characterize. An MRI without contrast can miss small meningiomas.
• Not a CT scan as the only study: CT scans are good for emergencies but frequently miss meningiomas, particularly smaller ones or those located at the skull base. If you are told a CT scan was "normal," this does not rule out a meningioma.

Keep a symptom journal for 2–3 weeks before your appointment. Document the character of your headaches (throbbing vs. pressure, morning vs. evening), any vision changes and when they occur, any episodes of imbalance, cognitive changes you have noticed, and any other neurological symptoms. A written log will help your physician understand the pattern and duration of your symptoms, which is important for clinical decision-making.

Seek a Second Opinion If Imaging Is Refused

If your primary care doctor declines to order an MRI and attributes your symptoms to migraine or another common condition, you have every right to seek a second opinion from a neurologist. You can also self-refer to a neurologist in most states. Be persistent: the symptoms of meningioma are real, your risk exposure from long-term Depo-Provera use is documented in peer-reviewed research, and you deserve a thorough evaluation.

Symptoms That Require Emergency Evaluation Right Now

These symptoms can indicate that a meningioma has grown to the point of causing dangerous compression of critical brain structures, or that a complication such as peritumoral edema (swelling around the tumor), hemorrhage into the tumor, or obstruction of cerebrospinal fluid circulation has occurred. All of these are neurosurgical emergencies. Do not wait for a scheduled appointment — go directly to a hospital emergency department and tell them you are a long-term Depo-Provera user who is concerned about a meningioma. They will order the appropriate imaging immediately.

Even if your symptoms are not at this emergency level, do not let them be dismissed. Persistent and progressive neurological symptoms in a long-term Depo-Provera user deserve investigation, not reassurance. The difference between a meningioma found at 2 cm and one found at 5 cm is the difference between a relatively straightforward surgery and a complex, high-risk operation with greater potential for permanent deficit. Earlier diagnosis leads to better outcomes, period.

The Legal Connection: What a Diagnosis Means for Your Rights

If you have been diagnosed with a meningioma and you used Depo-Provera for at least one year, you may be eligible to join the federal multidistrict litigation against Pfizer, the manufacturer of Depo-Provera. This is not a class action lawsuit — it is an MDL, which means individual cases are consolidated in one court for pretrial proceedings, but each case maintains its individual identity and will ultimately be resolved based on its specific facts.

The Basic Eligibility Criteria

While every case is evaluated individually, attorneys reviewing Depo-Provera meningioma claims generally look for:

• Use of injectable medroxyprogesterone acetate (Depo-Provera or its generic equivalents) for at least 12 consecutive months
• A diagnosis of intracranial meningioma confirmed by MRI imaging or surgical pathology
• Ideally, a meningioma that required surgical intervention (resection) or caused documented neurological harm — these cases are typically assigned higher value
• Cases where the meningioma was found during the period of Depo-Provera use or within several years after discontinuation

Statutes of limitations vary by state — typically two to three years from the date of diagnosis or from the date when you knew or reasonably should have known about the connection between your diagnosis and Depo-Provera use. Given that the FDA warning was issued in December 2025, many women are arguably still within the discovery period for their statute of limitations clock. However, the best course of action is to consult with an attorney as soon as possible, because legal deadlines are strict and no exceptions are made for delayed discovery after the limitations period has expired.

These cases are handled on a contingency fee basis — meaning you pay no attorney fees unless and until money is recovered on your behalf. There is no financial risk in having a free case evaluation.

Frequently Asked Questions